Compare Cytokinetics Inc (CYTK) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Cytokinetics Inc trades at $62.48 (market cap $8.62B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $25.11 (market cap $141.25M). The key difference: Cytokinetics Inc is far larger — about 61× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and ProShares UltraShort Bloomberg Natural Gas ETF is more actively traded (5,492,367 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days on average.
| CYTK | KOLD | |
|---|---|---|
Market Cap | $8.62B | $141.25M |
Volume | 2,594,626 | 5,492,367 |
Sector | Health | Leveraged / Inverse |
52-Week High | $87.26 | $49.39 |
52-Week Low | $54.76 | $13.58 |
Typical Hold Time | 19 Days | 10 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
KOLD is trading at $24.84, down 5.8% over the past 24 hours amid bearish technical signals. The stock faces significant selling pressure with moving averages indicating a strong downtrend, though oscillators remain neutral. Recent news highlights natural gas market volatility with record production levels and geopolitical tensions affecting energy sector sentiment. The stock currently trades near key support levels with resistance forming around $25-26.
The outlook remains challenging with bearish technical indicators and fundamental headwinds in the natural gas sector. Investment opportunities exist for contrarian investors betting on energy market recovery, but risks include continued production growth and weather-dependent demand. The stock's performance will likely track natural gas price movements and broader energy market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
